Title |
Combined corticosteroid and long‐acting beta<sub>2</sub>‐agonist in one inhaler versus long‐acting beta<sub>2</sub>‐agonists for chronic obstructive pulmonary disease
|
---|---|
Published in |
Cochrane database of systematic reviews, September 2012
|
DOI | 10.1002/14651858.cd006829.pub2 |
Pubmed ID | |
Authors |
Luis Javier Nannini, Toby J Lasserson, Phillippa Poole |
Abstract |
Both inhaled steroids (ICS) and long-acting beta(2)-agonists (LABA) are used in the management of chronic obstructive pulmonary disease (COPD). This updated review compared compound LABA plus ICS therapy (LABA/ICS) with the LABA component drug given alone. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 1 | 20% |
United States | 1 | 20% |
Unknown | 3 | 60% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 60% |
Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Scientists | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 334 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 3 | <1% |
Brazil | 1 | <1% |
Australia | 1 | <1% |
South Africa | 1 | <1% |
Russia | 1 | <1% |
Unknown | 327 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 48 | 14% |
Researcher | 42 | 13% |
Student > Bachelor | 38 | 11% |
Student > Ph. D. Student | 27 | 8% |
Other | 25 | 7% |
Other | 64 | 19% |
Unknown | 90 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 147 | 44% |
Nursing and Health Professions | 27 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 15 | 4% |
Social Sciences | 11 | 3% |
Agricultural and Biological Sciences | 7 | 2% |
Other | 28 | 8% |
Unknown | 99 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 September 2022.
All research outputs
#1,463,006
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#3,126
of 11,842 outputs
Outputs of similar age
#8,823
of 187,469 outputs
Outputs of similar age from Cochrane database of systematic reviews
#57
of 224 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,842 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.9. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,469 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 224 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.